In the 90s, we were able to create the unique technology for synthesis of the innovative biologically active substance under the technical name GLT 75257, and initiate and conduct research on its safety and efficiency. The substance has been studied for more than 20 years in laboratories, clinics, scientific research institutes and medical institutions in Ukraine. Being biologically active the substance is an adaptive chemical-thermodynamic system that has following effects and can:
- destroy selectively malignant cells and other cells with signs of mutations
- restore the ability of the regulatory mechanisms of the human body to withstand the action of toxins and infections
- effectively influence the quality indicators of people’s health, slowing down the age-related changes in the body.
CROWN FARMA implements an extensive project, which is important for the society globally. It promotes new effective high-performance medicines and other medical products created on the bases of innovative biologically active substance GLT 75257.
The goal of our company is development, preclinical and clinical research, and registration of new innovative medicines and products designed to treat complex and poorly treatable diseases as well as epidemiological and viral diseases. We focus attention on the drugs able to take a worthy place in Gerontology area as solving the rejuvenation issue is a top priority worldwide.
Unfortunately, the generally accepted modern protocols for the treatment of malignant tumours do not always give the expected results. Moreover, in many cases, the toxicity of the drugs and procedures used for treatment has an additional negative effect on the weakened body of the patient. The development of next-generation drugs is actively underway all over the world. Some progress has been made in the use of new cytotoxic and cytostatic drugs aimed at destroying tumour cells and/or suppressing their proliferative activity.
Anti-tumour drug CR 173487 was created by using the unique technology developed as a result of more than 20 years of scientific and medical research. The drug is classified within Cytostatics group.